G protein subunit alpha transducin 1Genealiases: CSNB1G · CSNBAD3 · GBT1 · GNATR · HG1F
Q-omics provides the consensus-scored GNAT1 profile across patient tissues and cancer cell-line models. GNAT1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, GNAT1 is differentially expressed in 8, with the highest sampling consensus in LIHC. Additionally, GNAT1 RNA expression shows 10,021 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight ACC, LIHC, and TGCT as cancer lineages where GNAT1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GNAT1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GNAT1 survival associations across molecular data types. GNAT1 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (1) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GNAT1 RNA expression–survival associations across cancer types. High GNAT1 expression shows unfavorable associations in ACC, MESO, KICH and CHOL, but favorable associations in SCLC and LUSC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify ACC as the clearest survival context for GNAT1 RNA expression.
This table summarizes GNAT1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for GNAT1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GNAT1 shows lower tumor expression in CHOL and HNSC and higher tumor expression in LIHC, BRCA, COAD and UCEC. The LIHC box plot shows higher GNAT1 RNA expression in tumor versus normal tissue (log2 FC = +0.480, t-test p < 0.001).
This table shows molecular features associated with GNAT1 in patient tissues and cancer cell lines. In patient samples, GNAT1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, GNAT1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and CNS.
